Biogen was founded on scientific excellence. We strive to improve the lives of those living with the diseases that we treat by continuing to advance research and development, and by including access and broader health considerations as early as possible in the drug development cycle.
Responsibility
Access and Health Equity
Advancing Health Access
Our therapies can change lives, but only if people can access them. That’s one reason why we aim to help strengthen health systems and work to provide access to our medicines, including for people living in low- and middle-income countries.
Evidence-based Clinical Trials
Health outcomes often depend on factors beyond the control of people and their doctors, such as disparities across age, gender, race, ethnicity, geographic locations globally and socioeconomic level. These disparities are compounded by factors ranging from inadequate representation in clinical trials to barriers to accessing care. We are committed to addressing health inequities for the disease areas we treat. By increasing participation of underrepresented populations in clinical trials, like in Alzheimer’s disease and lupus, we believe we can better serve a diverse range of patients.
Providing Medicines to Those in Need
Our Global Access Mechanisms are designed to help bridge gaps, and have become even more important as our pipeline continues to advance more innovative treatments for severe and life-threatening conditions where alternative treatments do not yet exist. Through ongoing collaboration with regulators, clinical researchers, ethicists, physicians and Patient Advocacy Groups (PAGs), we regularly evaluate and refine our approach so our access programs align with regulatory standards while reflecting our patient-focused values.
In this work, we consider Access to Medicine Index criteria, including:
- Governance of Access
- Research and Development
- Product Delivery
Affordability and Pricing
We strive to remove barriers to care by offering financial assistance and helping secure reimbursement in public and private healthcare programs. In some countries, we have developed tailored solutions to meet local needs.
Biogen’s increasing global operational footprint facilitates reaching more patients and helps us better understand local needs. We have worked with local health authorities and local partners to develop programs to support patients. One example is our value-based agreement in Saudi Arabia.
We regularly review our pricing strategy and prioritize patient access to our therapies. Learn more about our Pricing Principles.